OLMA

Olema Pharmaceuticals, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Harmon CyrusDirector
$26k3.1k shares
SellSep 18, 2025
$8.32
--
Harmon CyrusDirector
$15k1.9k shares
SellSep 16, 2025
$8.08
--
Harmon CyrusDirector
$83k10k shares
SellSep 18, 2025
$8.33
--
Harmon CyrusDirector
$80k10k shares
SellSep 16, 2025
$8.04
--
Zojwalla NaseemChief Medical Officer
$2.8M99.5k shares
SellDec 23, 2025
$27.66
--
Zojwalla NaseemChief Medical Officer
$2.8M100k shares
SellDec 22, 2025
$28.04
--

News

globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 2globenewswire.comOlema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancerglobenewswire.comMay 26globenewswire.comOlema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meetingglobenewswire.comMay 21globenewswire.comOlema Oncology to Participate in Upcoming Investor Conferencesglobenewswire.comMay 19globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comMay 4